The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

Scientific Events

Upcoming Scientific Events
Recent Scientific Presentations
THT 2022, New York & Online Congress

1-2 February, 2022
Presentation by Dr. Testani: “Direct Sodium Removal with the Sequana Medical alfapump DSR system”
download Presentation

KOL Webinar with Dr. Vargas and Dr. Knuttinen

July 15, 2021
“The Impact of Liver Ascites on Patients and Healthcare Systems and the potential of alfapump® therapy in NASH-related ascites”
Replay Webinar
Download presentation

Heart Failure 2021 Online Congress

29 June – 1 July, 2021
Presentation by Dr. Testani: “First in Human Experience with Alfapump DSR System in Diuretic Resistant Chronic Heart Failure”
download Presentation

KOL Webinar with Dr. Testani

11 December 2020
“The challenge of diuretic resistance in the management of heart failure patients and the potential for alfapump DSR therapy”
Replay webcast
Download presentation


2-5 October 2019, Wiesbaden, Germany
Presentation by Prof. Wong during lunch symposium on 4 October 2019: “Refractory Ascites: Reduce Fluid – Increase Quality of Life”


25-30 September 2019, San Francisco, US
Presentation by Dr. Testani on 28 September 2019: Direct Sodium Removal with an ambulatory peritoneal dialysis system


25-28 May 2019, Athens, Greece
Presentation by Dr. Testani during late-breaking session on 27 May 2019 (for webcast go to Investor Relations Events & Presentations page)


20-24 May 2019, Paris, France
Presentation by Ian Crosbie, CEO on 23 May 2019

The AASLD Liver Meeting

9-13 November 2018, San Francisco
Poster session on 10 November 2018 by Dr. Florence Wong


14-16 September 2018, Kyoto, Japan
Poster session on 15 September by Prof. Dr. Christina Fotopoulou

HFSA 22nd Annual Scientific Meeting

15-18 September 2018, Tennessee
Poster session on 16 September by Dr. Jeffrey Testani

Investor Relations Events

For Investor Relations Events & Presentations, please visit our Investors page.

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.